Abstract: Provided are novel polymer particles for carrying a physiologically active substance and a method of preparing the same. The polymer particles for carrying a physiologically active substance can provide an analytical reagent, which has high analytical precision and sensitivity and can be stably prepared; can easily and precisely control the amount of functional groups carrying the physiologically active substance; can introduce, onto the surface of latex particles, a hydrophilic compound for inhibiting a nonspecific reaction; and can be prepared to have a narrow and uniform particle size distribution.

Abstract: A shaft torque control device executes highly responsive shaft-torque control even when spring rigidity of a connection shaft connecting an engine and dynamometer varies, and has a feedback control system including a nominal plant imitating input-output characteristics of a test system, generalized plant having nominal plant; controller providing an input with use of outputs and variation term causing variation in the nominal plant on the basis of a variation transfer function. In the controller, setting is made to satisfy a design condition. Nominal plant is structured with a two-inertia system configured by connecting two inertia bodies via a shaft having spring rigidity equal to a predetermined nominal value set to be a lower limit value in an assumed variation range of spring rigidity of the connection shaft. The variation transfer function is a positive real function. Spring rigidity in the nominal plant Na increases from the nominal value.

Abstract: A seat with a ventilation system that maintains seated person's coolness by blowing air to minimum segments of a seatback and a seat cushion so that seated person's comfort is maintained is provided. Air-blowing means is controlled in air-blowing quantity and air-blowing time periodically by air-blowing control means, and air blowing in each period is set to include a first term T1 in which a predetermined quantity of air is blown and a second term T2 in which the predetermined quantity of air to be blown is gradually reduced.

Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: Shown is a method for producing a liquid crystal capsule having a particle diameter of 30 to 150 nanometers, and a method for producing a liquid crystal capsule without using a homogenizer. The disclosure concerns a method for producing a liquid crystal capsule, including a step of preparing an emulsion by performing phase inversion emulsification of a mixed material obtained by mixing a liquid crystal composition, a monomer, a surfactant, and a polymerization initiator; and a step of producing a liquid crystal capsule by applying a coacervation method to the emulsion. The disclosure also concerns a liquid crystal capsule having a liquid crystal composition, a surfactant and a capsule wall, wherein the capsule wall has a closed curved shape, the liquid crystal composition and a hydrophobic moiety of the surfactant are arranged inside the capsule wall, and a hydrophilic moiety of the surfactant is arranged outside the capsule wall.

Abstract: Methods of producing hepatocyte lineage cells are provided. The method can include transfecting a cell with one or more expression vectors. For example, a cell can be transfected with a first expression vector containing a first gene that encodes CCAAT/enhancer binding protein alpha (CEBPA), a second expression vector containing a second gene that encodes CCAAT/enhancer binding protein beta (CEBPB), a third expression vector containing a third gene that encodes forkhead box A1 (FOXA1), and a fourth expression vector containing a fourth gene that encodes forkhead box A3 (FOXA3). The method can include culturing the transfected cell obtained in a growth environment. The transfected cell can be cultured in Williams' E medium, ReproFF (feeder-free media maintaining pluripotency) medium, or both. Transfected and/or hepatocyte lineage cells obtained by a method of the present invention are also provided.

Abstract: Objects of the present invention are to find a marker by which progression of arteriosclerosis can be directly grasped, to thereby provide motivation for prevention or treatment of arteriosclerosis itself, and to provide means for accurately grasping condition of arteriosclerosis-related disease including arteriosclerotic disease. The invention provides a method for acquiring data on progression of arteriosclerosis, the method including determining a level of an antibody against SH3BP5 protein or a part thereof in a body fluid sample collected from a biological body, and a data acquisition kit for performing the data acquisition method.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A film having a metallic luster is easier to manufacture and exhibits little degradation over time, an article having the film formed thereon, and a manufacturing method for the film having a metallic luster. The film, which has a metallic luster, according to one aspect of the present invention, is characterized by containing a thiophene polymer. The manufacturing method for the film which has a metallic luster, according to another aspect of the present invention, is characterized by a thiophene being polymerized using an oxidizing agent and made into a solution containing the thiophene polymer, and then coating and drying the solution containing the thiophene polymer on an article. The article having the film which has a metallic luster formed thereon, according to another aspect of the present invention, is characterized by containing a thiophene polymer.

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.

Abstract: Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker.

Abstract: Provided is a liquid crystal compound that can obtain a high-speed response and a sufficient contrast ratio in switching of a display device. A compound represented by formula (1) described below is utilized. In formula (1), ring A is naphthylene, phenantolylene or anthracenylene, and in the groups, at least one piece of hydrogen may be replaced by halogen, —CH3, —C2H5, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2 or —OCH2F; and X1, X2, X3, X4, X5, Y1, Y2, Y3, Y4 and Y5 are independently hydrogen or fluorine, but at least two or more of X1, X2, X3, X4, X5, Y1, Y2, Y3, Y4 and Y5 is fluorine.

Abstract: Disclosed is a high quality display device which avoids complicated element structure, and does not unnecessarily reduce portability. The display device comprises: a pair of substrates which are disposed facing each other, and on each of which electrodes are formed; and a material layer which is sandwiched between the pair of substrates. The material layer contains: a coloring material which changes color upon the application of a voltage; and a light-emitting material which emits light upon photoexcitation.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A tunable external resonator laser is mode-hop-free for broadband and has a laser chip which emits light; a lens which collimates the light emitted from the laser chip, a diffraction grating which diffracts the light collimated by the lens, a support body to which the diffraction grating is fixed, and a movable mirror which reflects the light diffracted by the diffraction grating, wherein the diffraction grating is arranged a prescribed distance apart from a Littman-type tunable external resonator laser arrangement in which the movable mirror rotates on a pivot which is the intersection point of the surface of said movable mirror and the surface of the diffraction grating.

Abstract: The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other.